Little House Capital LLC Acquires 1,573 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Little House Capital LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 33.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,307 shares of the pharmaceutical company's stock after acquiring an additional 1,573 shares during the period. Little House Capital LLC's holdings in Vertex Pharmaceuticals were worth $3,058,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Mascagni Wealth Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth $31,000. Truvestments Capital LLC boosted its holdings in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after purchasing an additional 23 shares during the last quarter. Mpwm Advisory Solutions LLC bought a new stake in Vertex Pharmaceuticals in the 4th quarter worth about $40,000. Minot DeBlois Advisors LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $44,000. Finally, Prestige Wealth Management Group LLC lifted its position in shares of Vertex Pharmaceuticals by 45.5% during the 4th quarter. Prestige Wealth Management Group LLC now owns 112 shares of the pharmaceutical company's stock worth $45,000 after buying an additional 35 shares in the last quarter. Institutional investors own 90.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on VRTX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Leerink Partners reissued a "market perform" rating and issued a $503.00 price objective (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. Royal Bank Of Canada set a $420.00 target price on Vertex Pharmaceuticals and gave the stock a "sector perform" rating in a research note on Tuesday, June 17th. Finally, Wall Street Zen upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, March 11th. Fourteen equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $511.62.

Vertex Pharmaceuticals Price Performance

VRTX stock traded up $6.96 during midday trading on Tuesday, reaching $452.16. The company had a trading volume of 1,146,627 shares, compared to its average volume of 1,594,588. The firm has a 50-day moving average price of $453.85 and a 200-day moving average price of $458.59. The company has a market capitalization of $116.11 billion, a P/E ratio of -115.35 and a beta of 0.42. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the prior year, the company earned $4.76 EPS. The firm's revenue was up 2.6% compared to the same quarter last year. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.